Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bicara Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Bicara Therapeutics Inc.’s stock price such as:

• Bicara Therapeutics Inc.’s current stock price and volume
• Why Bicara Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for BCAX from analysts
• BCAX’s stock price momentum as measured by its relative strength

About Bicara Therapeutics Inc. (BCAX)

Before we jump into Bicara Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Want to learn more about Bicara Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bicara Therapeutics Inc..

Bicara Therapeutics Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Bicara Therapeutics Inc.’s stock price was $27.100.

Bicara Therapeutics Inc. is up 3.16% from its previous closing price of $26.270.

During the last market session, Bicara Therapeutics Inc.’s stock traded between $25.350 and $27.120. Currently, there are approximately 60.72 million shares outstanding for Bicara Therapeutics Inc..

Bicara Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Bicara Therapeutics Inc. Stock Price History

Bicara Therapeutics Inc.’s (BCAX) price is currently down 8.72% so far this month.

During the month of July, Bicara Therapeutics Inc.’s stock price has reached a high of $30.990 and a low of $25.350.

Over the last year, Bicara Therapeutics Inc. has hit prices as high as $30.990 and as low as $9.570. Year to date, Bicara Therapeutics Inc.’s stock is up 61.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bicara Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Bicara Therapeutics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Bicara Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bicara Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bicara Therapeutics Inc. (BCAX) by visiting AAII Stock Evaluator.

Relative Price Strength of Bicara Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Bicara Therapeutics Inc. has a weighted four-quarter relative price strength of 20.34%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Bicara Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bicara Therapeutics Inc. Stock Price: Bottom Line

As of July 31, 2026, Bicara Therapeutics Inc.’s stock price is $27.100, which is up 3.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bicara Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.